These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25788259)

  • 1. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.
    Pitman MR; Powell JA; Coolen C; Moretti PA; Zebol JR; Pham DH; Finnie JW; Don AS; Ebert LM; Bonder CS; Gliddon BL; Pitson SM
    Oncotarget; 2015 Mar; 6(9):7065-83. PubMed ID: 25788259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and evaluation of inhibitors of human sphingosine kinase.
    French KJ; Schrecengost RS; Lee BD; Zhuang Y; Smith SN; Eberly JL; Yun JK; Smith CD
    Cancer Res; 2003 Sep; 63(18):5962-9. PubMed ID: 14522923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases.
    Gao P; Peterson YK; Smith RA; Smith CD
    PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles, regulation and inhibitors of sphingosine kinase 2.
    Neubauer HA; Pitson SM
    FEBS J; 2013 Nov; 280(21):5317-36. PubMed ID: 23638983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
    French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
    J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of sphingosine kinase inhibitors.
    Pitman MR; Costabile M; Pitson SM
    Cell Signal; 2016 Sep; 28(9):1349-1363. PubMed ID: 27297359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
    Selvam SP; Ogretmen B
    Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine kinase 1 in cancer.
    Heffernan-Stroud LA; Obeid LM
    Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of the sphingosine kinase pathway as potential therapeutics.
    Pitman MR; Pitson SM
    Curr Cancer Drug Targets; 2010 Jun; 10(4):354-67. PubMed ID: 20370685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Sphingosine Kinases for the Treatment of Cancer.
    Lewis CS; Voelkel-Johnson C; Smith CD
    Adv Cancer Res; 2018; 140():295-325. PubMed ID: 30060814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells.
    Leroux ME; Auzenne E; Evans R; Hail N; Spohn W; Ghosh SC; Farquhar D; McDonnell T; Klostergaard J
    Prostate; 2007 Nov; 67(15):1699-717. PubMed ID: 17879964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.
    Shin KO; Seo CH; Cho HH; Oh S; Hong SP; Yoo HS; Hong JT; Oh KW; Lee YM
    Arch Pharm Res; 2014; 37(9):1183-92. PubMed ID: 24687256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response.
    Sordillo LA; Sordillo PP; Helson L
    Anticancer Res; 2016 May; 36(5):2085-95. PubMed ID: 27127108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b.
    Lim KG; Tonelli F; Berdyshev E; Gorshkova I; Leclercq T; Pitson SM; Bittman R; Pyne S; Pyne NJ
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1457-64. PubMed ID: 22634604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
    McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
    Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy.
    Gault CR; Obeid LM
    Crit Rev Biochem Mol Biol; 2011 Aug; 46(4):342-51. PubMed ID: 21787121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases.
    Adams DR; Pyne S; Pyne NJ
    Cell Signal; 2020 Dec; 76():109806. PubMed ID: 33035646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation.
    Ren S; Xin C; Pfeilschifter J; Huwiler A
    Cell Physiol Biochem; 2010; 26(1):97-104. PubMed ID: 20502009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of sphingosine kinase inhibitors.
    French KJ; Upson JJ; Keller SN; Zhuang Y; Yun JK; Smith CD
    J Pharmacol Exp Ther; 2006 Aug; 318(2):596-603. PubMed ID: 16632640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
    Alshaker H; Srivats S; Monteil D; Wang Q; Low CMR; Pchejetski D
    Breast Cancer Res Treat; 2018 Nov; 172(1):33-43. PubMed ID: 30043096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.